Excel Therapeutics to Launch Four New Culture Media Products This Year

"Targeting the Immunotherapy Market"
Expanding Culture Media Portfolio to T Cells, NK Cells, and Exosomes
Two AOF-Based Products Launched; Securing Chinese Clients and Distributors

Excel Therapeutics, a company specializing in cell and gene therapy (CGT) culture media, announced on September 15 that it will sequentially launch four new media products within the year.

The products Excel Therapeutics is preparing to release are ▲CellCor™ EXO CD AOF ▲CellCor™ T CD AOF ▲CellCor™ NK XF ▲CellCor™ MSC CD AOF. According to the company, all four products have completed process development and are currently undergoing technology transfer to the production division.

Image of the new patch product by Xcel Therapeutics. Xcel Therapeutics

CellCor™ EXO CD AOF and CellCor™ T CD AOF are based on chemically defined medium (CD) and xeno-free medium (XF), and incorporate the ‘AOF’ (Animal-Origin Free) technology that excludes animal-derived components. By eliminating both animal- and human-derived ingredients, these products offer improved raw material safety and consistency in the culture environment.

The EXO CD AOF product has signed Chinese company Xiangya Bio as a major customer and distributor, while T CD AOF has secured Bluemage Biotechnology as a key customer and distributor. Through the launch of its new products, Excel Therapeutics plans to expand its supply in international markets, including China.

CellCor™ NK XF is a dedicated medium developed to enable NK cell proliferation without the need for feeder cells. The company is currently in discussions to supply this product to new clients overseas, including those in China, and expects to broaden its customer base in the NK cell therapy sector.

The company's flagship product line MSC CD AOF will be expanded to include a version without phenol red, called ‘MSC CD AOF’. The intent is to diversify the product range so that various culture conditions can be accommodated during the cell therapy production process.

Haemin Jeong, Head of Research at Excel Therapeutics, stated, “These four new products have been developed based on demand from global clients and through technical validation. We will expand our application areas to immunotherapy products, such as T cell and NK cell therapies, and secure new customers and markets.”

This content was produced with the assistance of AI translation services.